#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16446	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2192	746.4	0	.	n	.	0	A69G	SNP	69	69	A	348	348	G	948	G,A	881,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16446	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2192	746.4	0	.	n	.	0	C1450T	SNP	1450	1450	C	1729	1729	T	901	T	828	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16446	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2192	746.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1463	1463	C	1014	C	946	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29968	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3584	832.7	0	.	n	.	0	T695C	SNP	695	695	T	968	968	C	941	C,T,G	887,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29968	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3584	832.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2244	2244	C	930	C	862	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29968	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3584	832.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2318	2318	A	876	A	833	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29968	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3584	832.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	2870	2870	C	914	C	870	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	2134	folP	855	855	100.0	folP.l15.c4.ctg.1	1489	142.1	1	SNP	p	R229S	1	.	.	685	687	AGC	1000	1002	AGC	207;207;206	A;G;C	189;186;185	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6142	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3411	179.3	1	SNP	p	S91F	1	.	.	271	273	TTC	596	598	TTC	206;207;206	T;T;C	190;189;187	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6142	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3411	179.3	1	SNP	p	G95N	0	.	.	283	285	GGC	608	610	GGC	204;203;203	G;G;C	185;184;184	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6142	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3411	179.3	1	SNP	p	D95G	1	.	.	283	285	GGC	608	610	GGC	204;203;203	G;G;C	185;184;184	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1954	mtrR	633	633	99.84	mtrR.l15.c30.ctg.1	1262	153.6	0	.	p	.	0	D79N	NONSYN	235	237	GAT	562	564	AAT	242;244;243	A,G;A;T	223,1;226;221	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1954	mtrR	633	633	99.84	mtrR.l15.c30.ctg.1	1262	153.6	1	SNP	p	G45D	0	.	.	133	135	GGC	460	462	GGC	252;248;246	G;G,A;C	243;234,1;234	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1052	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1099	95.3	0	.	n	.	0	A197.	DEL	197	197	A	619	619	A	236	A	219	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5576	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2941	188.8	0	.	p	.	0	E91G	NONSYN	271	273	GAG	597	599	GGG	201;201;199	G;G;G,T	191;192;192,1	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5576	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2941	188.8	1	SNP	p	D86N	0	.	.	256	258	GAC	582	584	GAC	195;192;194	G;A;C	183;182;186	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5576	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2941	188.8	1	SNP	p	S87W	0	.	.	259	261	AGT	585	587	AGT	196;194;195	A;G;T	185;188;186	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5576	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2941	188.8	1	SNP	p	S87R	0	.	.	259	261	AGT	585	587	AGT	196;194;195	A;G;T	185;188;186	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5576	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2941	188.8	1	SNP	p	S87I	0	.	.	259	261	AGT	585	587	AGT	196;194;195	A;G;T	185;188;186	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5576	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2941	188.8	1	SNP	p	S88P	0	.	.	262	264	TCC	588	590	TCC	192;192;191	T;C;C	184;182;182	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	5032	parE	1986	1986	99.95	parE.l15.c30.ctg.1	2707	185.2	0	.	p	.	0	R427H	NONSYN	1279	1281	CGC	1639	1641	CAC	259;258;256	C;A;C	233;235;233	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	5032	parE	1986	1986	99.95	parE.l15.c30.ctg.1	2707	185.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1588	1590	GGC	267;265;261	G;G;C	250;245;239	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.44.001	penA.44.001	1	1	27	4588	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2462	185.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1287	1289	GCA	251;250;251	G;C;A	230;229;236	penA.44.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4588	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2462	185.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1290	1292	ATC	251;250;250	A;T,A;C	238;235,1;230	penA.44.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4588	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2462	185.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1302	1304	GTG	248;249;247	G;T;G	231;229;231	penA.44.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4588	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2462	185.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1302	1304	GTG	248;249;247	G;T;G	231;229;231	penA.44.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4588	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2462	185.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1806	1808	ACC	238;238;241	A;C;C	216;217;221	penA.44.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4588	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2462	185.9	1	SNP	p	T502V	0	.	.	1504	1506	ACG	1860	1862	ACG	220;218;216	A,G;C;G	181,1;182;181	penA.44.001:1:1:T502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4588	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2462	185.9	1	SNP	p	T502P	0	.	.	1504	1506	ACG	1860	1862	ACG	220;218;216	A,G;C;G	181,1;182;181	penA.44.001:1:1:T502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4588	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2462	185.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1983	1985	GGC	214;213;215	G;G;C	190;190;193	penA.44.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4588	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2462	185.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1992	1994	GGC	211;209;205	G;G;C	189;190;185	penA.44.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4588	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2462	185.9	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2010	2012	CTG	202;201;198	C,G;T;GCCC,GCCCC	152,9;145;152,1	penA.44.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6822	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3083	220.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1563	1565	CCG	231;230;228	C;C,A;G	211;217,1;212	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2470	porA	1146	1146	99.65	porA.l6.c17.ctg.1	1898	129.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	533	533	C	169	C	156	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3344	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1426	231.8	0	.	p	.	0	T26A	NONSYN	76	78	ACC	319	321	GCC	280;282;286	G;C;C	263;264;266	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3344	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1426	231.8	0	.	p	.	0	N38E	NONSYN	112	114	AAT	355	357	GAA	285;290;289	G;A;A	274;277;274	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3344	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1426	231.8	0	.	p	.	0	N124S	NONSYN	370	372	AAT	613	615	AGT	283;277;279	A;G,T;T	266;258,1;262	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3344	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1426	231.8	0	.	p	.	0	N134D	NONSYN	400	402	AAT	643	645	GAT	271;275;275	G;A;T	255;260;261	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3344	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1426	231.8	0	.	p	.	0	P175S	NONSYN	523	525	CCA	766	768	TCA	253;255;259	T;C;A	236;237;242	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3344	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1426	231.8	0	.	p	.	0	A218V	NONSYN	652	654	GCC	895	897	GTC	253;249;249	G;T;C	230;227;231	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3344	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1426	231.8	0	.	p	.	0	F222S	NONSYN	664	666	TTT	907	909	TCT	247;247;250	T;C;T	233;234;238	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3344	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1426	231.8	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1225	1227	GCA	283;285;284	G;C;A	271;273;274	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3344	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1426	231.8	1	SNP	p	G120K	1	.	.	358	360	AAG	601	603	AAG	271;268;268	A;A;G	256;252;255	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3344	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1426	231.8	1	SNP	p	D121N	0	.	.	361	363	GAC	604	606	GAC	267;269;269	G;A;C	252;254;255	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3344	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1426	231.8	1	SNP	p	A121D	1	.	.	361	363	GAC	604	606	GAC	267;269;269	G;A;C	252;254;255	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	11942	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5031	236.7	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2120	2122	CAT	256;255;256	C;A;T	245;242;243	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1288	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1102	116.3	1	SNP	p	V57M	1	.	.	169	171	ATG	562	564	ATG	273;272;269	A;T;G	257;257;255	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
